CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
gp100 antigen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00019448
NCT00019448Phase 2Completed
CompareCT.gov

Phase II Study of DNA Encoding the gp100 Antigen Alone or in Combination With Interleukin-2 in Patients With Recurrent Metastatic Melanoma

National Cancer Institute (NCI)·interventional·Posted Mar 5, 2007·Updated Mar 4, 2024

In Brief

A Phase 2 clinical trial evaluating gp100 antigen and interleukin-2 for Stage IV Melanoma and Recurrent Melanoma. Completed, across 1 site.

Detailed Summary

RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients with metastatic melanoma that has not responded to previous treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Melanoma, Recurrent Melanoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 5, 2007
Enrollment StartSep 1, 1998
Study CompletionMar 1, 2007
TodayJul 1, 2026
Posted 19.3 years ago

Interventions

gp100 antigendrug

interleukin-2drug